La chemioterapia adiuvante concomitante del carcinoma pancreatico

Translated title of the contribution: Adjuvant concomitant chemotherapy in pancreas cancer

Daniele Turci, Anna Cariello, Ugo De Giorgi, Maurizio Marangolo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Pancreatic cancer is a leading cause of cancer death. Despite improvement in diagnosis and treatment in the last 15 years, mortality rates essentially equal the incidence of the disease. Combination treatment with chemoradiation yields up to now better results than chemotherapy or radiotherapy given alone in consideration of substantial radio and chemoresistance of the cancer cells. This study will review the most important literature data about combination adjuvant treatment and preoperative (primary) chemoradiation in pancreatic cancer. Some other reports will be given on locoregional chemotherapy and finally a brief view on a possible perspective for promising future treatments coming from data of molecular pathology. Adjuvant chemoradiation after surgery has been shown to be superior to operation alone in potentially resectable pancreatic cancer in many studies, in terms both of local control and median overall survival. Unfortunately, a consistent percentage of patients cannot receive adjuvant treatment since late recovery after surgery or post-operative morbidity. Owing to this last reason, many authors prefer primary chemoradiation in potentially resectable pancreatic cancer; neoadjuvant treatment find out its background in other relevant biological and clinical evaluations. Some studies report encouraging results with primary chemoradiation using 5- fluorouracil. Other experiences with relatively new drugs, with potent radiosensitizing effect, such as gemcitabine or taxol are going on; many of these are phase I studies. Clinical research in the field of preoperative treatment is up to now emerging in some important Oncological Institutions. The principal actual aim seems to be that of foresee periods of treatment which will be brief and use the dose of chemotherapy that is active, giving acceptable toxicity. Ongoing trials will give, in the next years, the answer about the improvement of efficacy of treatments largely expected by all researchers.

Original languageItalian
JournalTumori
Volume85
Issue number1 SUPPL. 1
Publication statusPublished - 1999

Fingerprint

Adjuvant Chemotherapy
Pancreatic Neoplasms
gemcitabine
Drug Therapy
Therapeutics
Radiation-Sensitizing Agents
Neoadjuvant Therapy
Molecular Pathology
Paclitaxel
Radio
Fluorouracil
Cause of Death
Neoplasms
Radiotherapy
Research Personnel
Morbidity
Survival
Mortality
Incidence
Research

ASJC Scopus subject areas

  • Cancer Research

Cite this

Turci, D., Cariello, A., De Giorgi, U., & Marangolo, M. (1999). La chemioterapia adiuvante concomitante del carcinoma pancreatico. Tumori, 85(1 SUPPL. 1).

La chemioterapia adiuvante concomitante del carcinoma pancreatico. / Turci, Daniele; Cariello, Anna; De Giorgi, Ugo; Marangolo, Maurizio.

In: Tumori, Vol. 85, No. 1 SUPPL. 1, 1999.

Research output: Contribution to journalArticle

Turci, D, Cariello, A, De Giorgi, U & Marangolo, M 1999, 'La chemioterapia adiuvante concomitante del carcinoma pancreatico', Tumori, vol. 85, no. 1 SUPPL. 1.
Turci D, Cariello A, De Giorgi U, Marangolo M. La chemioterapia adiuvante concomitante del carcinoma pancreatico. Tumori. 1999;85(1 SUPPL. 1).
Turci, Daniele ; Cariello, Anna ; De Giorgi, Ugo ; Marangolo, Maurizio. / La chemioterapia adiuvante concomitante del carcinoma pancreatico. In: Tumori. 1999 ; Vol. 85, No. 1 SUPPL. 1.
@article{abf7238be3234c04931fd350e6745ede,
title = "La chemioterapia adiuvante concomitante del carcinoma pancreatico",
abstract = "Pancreatic cancer is a leading cause of cancer death. Despite improvement in diagnosis and treatment in the last 15 years, mortality rates essentially equal the incidence of the disease. Combination treatment with chemoradiation yields up to now better results than chemotherapy or radiotherapy given alone in consideration of substantial radio and chemoresistance of the cancer cells. This study will review the most important literature data about combination adjuvant treatment and preoperative (primary) chemoradiation in pancreatic cancer. Some other reports will be given on locoregional chemotherapy and finally a brief view on a possible perspective for promising future treatments coming from data of molecular pathology. Adjuvant chemoradiation after surgery has been shown to be superior to operation alone in potentially resectable pancreatic cancer in many studies, in terms both of local control and median overall survival. Unfortunately, a consistent percentage of patients cannot receive adjuvant treatment since late recovery after surgery or post-operative morbidity. Owing to this last reason, many authors prefer primary chemoradiation in potentially resectable pancreatic cancer; neoadjuvant treatment find out its background in other relevant biological and clinical evaluations. Some studies report encouraging results with primary chemoradiation using 5- fluorouracil. Other experiences with relatively new drugs, with potent radiosensitizing effect, such as gemcitabine or taxol are going on; many of these are phase I studies. Clinical research in the field of preoperative treatment is up to now emerging in some important Oncological Institutions. The principal actual aim seems to be that of foresee periods of treatment which will be brief and use the dose of chemotherapy that is active, giving acceptable toxicity. Ongoing trials will give, in the next years, the answer about the improvement of efficacy of treatments largely expected by all researchers.",
keywords = "Adjuvant concomitant chemotherapy, Pancreatic cancer, Primary chemoradiation",
author = "Daniele Turci and Anna Cariello and {De Giorgi}, Ugo and Maurizio Marangolo",
year = "1999",
language = "Italian",
volume = "85",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "1 SUPPL. 1",

}

TY - JOUR

T1 - La chemioterapia adiuvante concomitante del carcinoma pancreatico

AU - Turci, Daniele

AU - Cariello, Anna

AU - De Giorgi, Ugo

AU - Marangolo, Maurizio

PY - 1999

Y1 - 1999

N2 - Pancreatic cancer is a leading cause of cancer death. Despite improvement in diagnosis and treatment in the last 15 years, mortality rates essentially equal the incidence of the disease. Combination treatment with chemoradiation yields up to now better results than chemotherapy or radiotherapy given alone in consideration of substantial radio and chemoresistance of the cancer cells. This study will review the most important literature data about combination adjuvant treatment and preoperative (primary) chemoradiation in pancreatic cancer. Some other reports will be given on locoregional chemotherapy and finally a brief view on a possible perspective for promising future treatments coming from data of molecular pathology. Adjuvant chemoradiation after surgery has been shown to be superior to operation alone in potentially resectable pancreatic cancer in many studies, in terms both of local control and median overall survival. Unfortunately, a consistent percentage of patients cannot receive adjuvant treatment since late recovery after surgery or post-operative morbidity. Owing to this last reason, many authors prefer primary chemoradiation in potentially resectable pancreatic cancer; neoadjuvant treatment find out its background in other relevant biological and clinical evaluations. Some studies report encouraging results with primary chemoradiation using 5- fluorouracil. Other experiences with relatively new drugs, with potent radiosensitizing effect, such as gemcitabine or taxol are going on; many of these are phase I studies. Clinical research in the field of preoperative treatment is up to now emerging in some important Oncological Institutions. The principal actual aim seems to be that of foresee periods of treatment which will be brief and use the dose of chemotherapy that is active, giving acceptable toxicity. Ongoing trials will give, in the next years, the answer about the improvement of efficacy of treatments largely expected by all researchers.

AB - Pancreatic cancer is a leading cause of cancer death. Despite improvement in diagnosis and treatment in the last 15 years, mortality rates essentially equal the incidence of the disease. Combination treatment with chemoradiation yields up to now better results than chemotherapy or radiotherapy given alone in consideration of substantial radio and chemoresistance of the cancer cells. This study will review the most important literature data about combination adjuvant treatment and preoperative (primary) chemoradiation in pancreatic cancer. Some other reports will be given on locoregional chemotherapy and finally a brief view on a possible perspective for promising future treatments coming from data of molecular pathology. Adjuvant chemoradiation after surgery has been shown to be superior to operation alone in potentially resectable pancreatic cancer in many studies, in terms both of local control and median overall survival. Unfortunately, a consistent percentage of patients cannot receive adjuvant treatment since late recovery after surgery or post-operative morbidity. Owing to this last reason, many authors prefer primary chemoradiation in potentially resectable pancreatic cancer; neoadjuvant treatment find out its background in other relevant biological and clinical evaluations. Some studies report encouraging results with primary chemoradiation using 5- fluorouracil. Other experiences with relatively new drugs, with potent radiosensitizing effect, such as gemcitabine or taxol are going on; many of these are phase I studies. Clinical research in the field of preoperative treatment is up to now emerging in some important Oncological Institutions. The principal actual aim seems to be that of foresee periods of treatment which will be brief and use the dose of chemotherapy that is active, giving acceptable toxicity. Ongoing trials will give, in the next years, the answer about the improvement of efficacy of treatments largely expected by all researchers.

KW - Adjuvant concomitant chemotherapy

KW - Pancreatic cancer

KW - Primary chemoradiation

UR - http://www.scopus.com/inward/record.url?scp=22244461224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22244461224&partnerID=8YFLogxK

M3 - Articolo

C2 - 10235079

AN - SCOPUS:22244461224

VL - 85

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 1 SUPPL. 1

ER -